Cargando…

Characteristics of patients with severe, uncontrolled, eosinophilic asthma enrolled in a French cohort

BACKGROUND AND OBJECTIVE: Benralizumab (Fasenra(™)) has recently been approved as add-on maintenance treatment for adult patients with severe eosinophilic asthma inadequately controlled despite high-dosage inhaled corticosteroids plus long-acting β(2)-agonists. We aimed to identify and describe the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aubier, Michel, Thabut, Gabriel, Fabry-Vendrand, Caroline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124449/ https://www.ncbi.nlm.nih.gov/pubmed/30214249 http://dx.doi.org/10.2147/JAA.S170866

Ejemplares similares

Characteristics of Severe Non-Eosinophilic Asthma: Analysis of Data from 1075 Patients Included in the FASE-CPHG Study
por: Portel, Laurent, et al.
Publicado: (2023)

AZD7442 utilization for Pre-Exposure Prophylaxis Against COVID-19 in a French Early Access Program
por: Artaud, C, et al.
Publicado: (2023)

Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma
por: Park, Hae-Sim, et al.
Publicado: (2019)

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
por: Chapman, Kenneth R., et al.
Publicado: (2019)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life()
por: Bagnasco, Diego, et al.
Publicado: (2021)

Bronchial thermoplasty: a new therapeutic option for the treatment of severe, uncontrolled asthma in adults
por: Dombret, Marie-Christine, et al.
Publicado: (2014)

Use and persistence of single and multiple inhaler triple therapy prescribed for patients with COPD in France: a retrospective study on THIN database (OPTI study)
por: Deslee, Gaétan, et al.
Publicado: (2023)

Rapid effect of benralizumab in fulminant eosinophilic myocarditis in the setting of uncontrolled eosinophilic asthma
por: Goyack, Laura, et al.
Publicado: (2023)

Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population
por: Kerkhof, Marjan, et al.
Publicado: (2018)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2021)

Efficacy of Biologics in Severe, Uncontrolled Asthma Stratified by Blood Eosinophil Count: A Systematic Review
por: Korn, Stephanie, et al.
Publicado: (2023)

Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma
por: O’Quinn, Sean, et al.
Publicado: (2019)

Efficacy of Biologics on Refractory Eosinophilic Otitis Media Associated with Bronchial Asthma or Severe Uncontrolled CRSwNP
por: De Corso, Eugenio, et al.
Publicado: (2022)

A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
por: Davison, John, et al.
Publicado: (2021)

Severe eosinophilic asthma in Chinese C‐BIOPRED asthma cohort
por: Zhang, Qingling, et al.
Publicado: (2022)

Laryngomalacia presenting as severe uncontrolled asthma
por: Tamura, Kanami, et al.
Publicado: (2018)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
por: Kayser, Moritz Z, et al.
Publicado: (2021)

Severe Eosinophilic Asthma
por: Bakakos, Agamemnon, et al.
Publicado: (2019)

Both fractional exhaled nitric oxide and sputum eosinophil were associated with uncontrolled asthma
por: Gao, Jie, et al.
Publicado: (2018)

Effect of benralizumab in a patient with uncontrolled severe eosinophilic asthma and comorbid chronic rhinosinusitis with nasal polyps refractory to mepolizumab treatment
por: Mansur, Adel H.
Publicado: (2021)

An algorithmic approach for the treatment of severe uncontrolled asthma
por: Zervas, Eleftherios, et al.
Publicado: (2018)

Contribution of allergy in the acquisition of uncontrolled severe asthma
por: Delgado Dolset, María Isabel, et al.
Publicado: (2022)

Patients with Severe Uncontrolled Asthma: Perception of Asthma Control and its Management
por: George, Maureen, et al.
Publicado: (2022)

Eosinophilic bioactivities in severe asthma
por: Carr, Tara F., et al.
Publicado: (2016)

Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity?
por: Van Hulst, Glenn, et al.
Publicado: (2021)

Multiple manifestations of uncontrolled asthma increase the risk of severe COVID-19
por: Selberg, Stina, et al.
Publicado: (2023)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma
por: Gao, Jie, et al.
Publicado: (2018)

Baseline Characteristics of Patients Enrolled in Clinical Trials of Biologics for Severe Asthma as Potential Predictors of Outcomes
por: Menzella, Francesco
Publicado: (2023)

Biological function of eosinophil extracellular traps in patients with severe eosinophilic asthma
por: Choi, Youngwoo, et al.
Publicado: (2018)

Dupilumab efficacy in adolescents with uncontrolled, moderate‐to‐severe asthma: LIBERTY ASTHMA QUEST
por: Maspero, Jorge F., et al.
Publicado: (2021)

Targeting eosinophils: severe asthma and beyond
por: Caminati, Marco, et al.
Publicado: (2019)

Bronchial Thermoplasty in Patients with Severe Uncontrolled Asthma: First Korean Cases
por: Kang, Jieun, et al.
Publicado: (2019)

Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
por: Castro, Mario, et al.
Publicado: (2020)

Tiotropium as an Add-on Treatment Option for Severe Uncontrolled Asthma in Preschool Patients
por: Zielen, Stefan, et al.
Publicado: (2021)

Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
por: Liu, Mark C., et al.
Publicado: (2021)

Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma
por: Corren, Jonathan, et al.
Publicado: (2021)

Eosinophil‐derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma
por: Howarth, Peter, et al.
Publicado: (2020)

Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab
por: Jackson, David J., et al.
Publicado: (2020)

Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme
por: Taillé, Camille, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s976oao32h5kh1s50rcs3vp849